Medios AG (OTCMKTS:MEDOF – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 2,705 shares, a growth of 215.3% from the September 30th total of 858 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.
Medios Stock Performance
MEDOF opened at C$13.64 on Thursday. The company’s 50 day moving average is C$13.64 and its 200-day moving average is C$13.64. Medios has a 1-year low of C$13.64 and a 1-year high of C$13.64.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Medios in a report on Thursday, August 13th. One analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the company has a consensus rating of “Buy”.
About Medios
Medios AG is a Germany-based specialty pharmaceutical company headquartered in Berlin. The company focuses on supplying medicines and services for complex, often chronic or rare diseases, supporting healthcare providers and pharmacies involved in specialized patient care.
Its activities include the procurement, distribution and supply of specialty pharmaceuticals, as well as the preparation of patient-specific medications. Medios also provides pharmaceutical compounding services, producing individualized therapies in accordance with medical prescriptions and applicable quality standards.
Medios serves customers primarily in Germany through relationships with pharmacies, hospitals, medical practices and other healthcare partners.
Further Reading
- Five stocks we like better than Medios
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Medios Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medios and related companies with MarketBeat.com's FREE daily email newsletter.
